WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Summary

bioAffinity Technologies completed a $4 million registered direct offering and concurrent private placement of common stock priced at-the-market under Nasdaq rules, with WallachBeth Capital arranging the transaction.